NYXH Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 3.41
- P/S (TTM)
- 9.14
- EV/EBITDA
- -2.00
Profitability & growth
- ROE (TTM)
- -130.0%
- Operating margin
- -321.7%
- Revenue growth YoY
- 498.9%
- Dividend yield
- —
- Beta
- 0.96
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Nyxoah
Company profileNyxoah is an innovative medical technology firm dedicated to advancing treatment options for obstructive sleep apnea (OSA) through its proprietary Genio system, which employs minimally invasive hypoglossal nerve stimulation. The company is committed to clinical validation and extensive research to enhance patient outcomes and quality of life for individuals affected by OSA. By prioritizing innovation in the sleep medicine domain and fostering strategic partnerships, Nyxoah is strategically positioned to leverage the growing demand for effective OSA treatments, indicating strong prospects for…
Classification
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT, BELGIUM
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer